Browse / Tirzepatide

Tirzepatide

Dual GIP/GLP-1 agonist

Injectable Start 2.5 mg weekly, escalate every 4 weeks Same day each week EXTENSIVE (LICENSED DRUG)

Overview

What is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. Licensed drug products exist in some markets for diabetes and weight management; catalog research vials are not those licensed presentations. All catalog material is for laboratory research use only.

Key Benefits

Dramatic weight-change figures in licensed-drug trials (often cited 15–22% range), dual-incretin pharmacology, glycemic control, appetite suppression, body-composition research interest.

Mechanism of Action

GIP plus GLP-1 agonism is studied for insulin secretion, gastric emptying, and energy intake. SURPASS and SURMOUNT programs are the main clinical evidence base for the approved molecule.

Quick Start Guide

Typical Dose Start 2.5 mg weekly, escalate every 4 weeks
How Often Same day each week, any time of day
Where to Inject Thigh, abdomen (2+ inches from navel), upper arm
Injection Timing Any time of day, with or without food
Effects Timeline Appetite reduction 1–3 days, weight loss 2–4 weeks, peak effects 12–20 weeks
Storage Refrigerate 2–8°C, never freeze, protect from light
Cycle Length 12–24+ weeks minimum for full metabolic readouts
Break Between Not applicable — continuous therapy in trials

Molecular Information

Weight: 4,813.55 Da
Length: 39 amino acids
Type: Dual GLP-1/GIP agonist

Research directions

Glycemic programs Extensive (licensed drug)

SURPASS program

Weight programs Extensive (licensed drug)

SURMOUNT program

Pharmacokinetics

Peak ~24–48 h after weekly clinical doses

Half-life ~5 days

Cleared multi-week

PK of the licensed drug; not instructions for research vials.

Literature

SURMOUNT-1 — 2022 · Clinical. Tirzepatide in obesity.